Introduction
Epilepsy is one of the most common neurological conditions, with about 65 million people affected worldwide [1] . It is a chronic medical problem that requires long-term or lifelong therapy with antiepileptic drugs (AEDs), particularly for those patients with refractory epilepsy [2] . However, prolonged use of AEDs is known to be associated with adverse effects such as metabolic and organ toxicity, endocrine disturbance, negative cognitive effects, and psychiatric problems [3] [4] [5] [6] , particularly with alterations in thyroid function in patients with epilepsy [7] .
Thyroid hormones are essential for the development and regulation of the metabolic state of many tissues; thus, disturbances of thyroid function may impede growth and development in children and adversely affect endocrine hemostasis in adults [2] . Oppenheimer and McPherson [8] first recognized the alteration of thyroid hormones levels in epileptic patients taking phenytoin (PHT). Thereafter, a number of studies were performed to evaluate the thyroid profiles in patients with epilepsy, but with inconsistent results. Several studies suggested there was no change in the thyroid hormone profile among patients taking AEDs [9] [10] [11] , while others revealed AEDs might be significantly associated with alteration of thyroid hormones [7, [12] [13] [14] [15] . With this background, we aimed to conduct a meta-analysis to study the association between AED use and thyroid hormones in patients with epilepsy.
Purpose: As antiepileptic drugs (AEDs) are known to be associated with alterations in thyroid profiles, we aimed to carry out a meta-analysis to comprehensively assess the effects of AEDs on thyroid hormones in patients with epilepsy. Methods: We searched the NCBI (PubMed), ISI Web of Science, EMBASE databases, and Cochrane Library to identify studies evaluating the association between AED use and thyroid hormone profiles in patients with epilepsy. Fixed or random effects meta-analysis was used to pool results across studies. Results: In all, 35 studies were included in our analysis. Out of a total of 997 patients in these studies, epileptic patients receiving AEDs showed an overall significant decrease in thyroxin (T4) and free T4 (fT4) and higher levels of thyroid stimulating hormone (TSH) than the controls (T4: standardized mean difference [SMD] = À1.839, 95% confidence interval [CI], À2.063 to À1.614; fT4: SMD = À1.190, 95% CI, À1.687 to À0.692; TSH: SMD = 0.445, 95% CI, 0.031-0.858). Notably, the use of carbamazepine (CBZ) suggested a significant decrease in triiodothyronine (T3), T4, and fT4; phenytoin (PHT) use showed a decrease in T4 and fT4; and valproic acid (VPA) use was associated with decreased T4 and increased TSH. Conclusion: Our study suggests that use of AEDs such as CBZ, PHT, and VPA, was associated with alteration of thyroid hormones among patients with epilepsy.
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between January 1980 and April 2015. Only English language articles were considered. The search terms included ''antic-
''triiodothyronine (T3),'' ''free triiodothyronine (fT3),'' ''thyroxine (T4),'' ''free thyroxine (fT4),'' and ''thyrotropin (TSH).'' The above listed AEDs are the most commonly prescribed and widely used drugs to treat epilepsy. We retrieved all relevant articles and searched reference lists to identify as many studies as possible.
Eligibility criteria
Studies were included if they met the following criteria: (i) original data from epidemiologic reports with healthy controls; (ii) cross-sectional, case-control, or cohort studies that evaluated the association between AEDs and thyroid hormones in patients with epilepsy; (iii) the exposure was AEDs; (iv) measured thyroid hormones and expressed the data as means with standard deviations (SDs); (v) met at least six Newcastle-Ottawa Scale (NOS) criteria [17] -an eight-item tool with up to nine possible points, which was developed to assess the quality of observational studies to be included in systematic reviews and meta-analysis.
Data extraction
Two authors (ZYX and CHS) evaluated the studies and abstracted all relevant information independently using a unified data form. Divergences were discussed and resolved by a third author (QLL). The following data were collected from each study: author, year, country, study design, population, age, gender, AEDs, exposure duration and measurements of thyroid hormones (T3, fT3, T4, fT4, and TSH) in patients with epilepsy and healthy controls.
Data analysis
Considering the different assays in different studies, values of thyroid hormones were expressed as standardized mean difference (SMD). Statistical heterogeneity was examined using the I 2 statistic; P < 0.10 was considered significant. A value of 0% suggests no observed heterogeneity, whereas large values indicate increasing heterogeneity. Thus, P < 0.10 and I 2 value >50% indicate significant heterogeneity. When substantial heterogeneity was detected, we performed the summary estimate on the random effect model using the DerSimonian and Laird method. Otherwise, the fixed effect model using the Mantel and Haenszel method was used. To assess the influence of individual results on the pooled estimate, we conducted sensitivity analysis by excluding each study one by one, and recalculating the combined estimates for the remaining studies. According to the definition of children as per The United Nations Convention on the Rights of the Child, the population was stratified into child group (<18 years old) and adult group (>18 years old); subgroup analysis was thus performed by age. We carried out Egger's test and Begg's test to examine publication bias, P < 0.05 was considered to represent significant publication bias. All data analysis was performed using STATA/ SE12.0 (Stata, TX, College Station, USA).
Results

Study characteristics
As shown in Fig. 1 , our search identified 35 studies about AEDs and thyroid hormones [9, 10, 15, . The study details are described in Table 1 . Twelve studies [10, 20, 23, 25, 27, 33, 35, 38, 39, 41, 42, 44] with a total of 997 participants described the association between various AEDs and thyroid hormones; of these, 11 were cross-sectional studies [10, 20, 23, 27, 33, 35, 38, 39, 41, 42, 44] , and one was a case-control study [25] . Four of 12 studies [25, 27, 33, 38] included only pediatric patients, 3 included only adults [20, 23, 42] , and 5 had a mixed patient population. Moreover, 25 studies [9, 10, 15, 18, 19, [21] [22] [23] [24] [26] [27] [28] [29] [30] [31] [32] [33] [34] [36] [37] [38] [39] [40] 43, 45] focused on specific AEDs, including 17 studies on VPA, 19 on CBZ, and 6 on PHT.
Use of AEDs and thyroid hormones
Overall, compared to controls, patients with epilepsy receiving AEDs showed a significant decrease in T4 and fT4, but higher TSH levels (T4: standardized mean difference For the sensitivity analysis, we recalculated the combined results by excluding one study per iteration; the results obtained were similar without significant fluctuations. For T4, the study-specific SMD ranged from a low value of À1.927 (95% CI, À2.172 to À1.681) by omission of the study by Rozza et al. [42] to a high value of À1.786 (95% CI, À2.051 to À1.521) by omission of the study by Tiihonen et al. [35] . For fT4, the study-specific SMD ranged from a low value of À1.344 (95% CI, À1.670 to À1.019) by omission of the study by Hamed et al. [20] to a high value of À1.111 (95% CI, À1.627 to À0.594) by omission of the study by Verrotti et al. [33] . For TSH, the studyspecific SMD ranged from a low value of 0.338 (95% CI, À0.060 to 0.736) by omission of the study by Rozza et al. [42] to a high value of 0.579 (95% CI, 0.297-0.860) by omission of the study by Rao et al. [41] .
Subgroup analysis by age (<18 vs. >18 years) showed significant SMDs were found in the child group (T4: SMD = À1.934; 1.934; 95% CI, À2.379 to À1.490; fT4: SMD = À1.450; 95% CI, À1.899 to À1.002; TSH: SMD = 0.635; 95% CI, 0.088-1.182).
Some specific AEDs and thyroid hormones
When evaluating the association between CBZ and thyroid hormones, a significant decrease in T3, T4, and fT4 was observed among patients on CBZ monotherapy (T3: SMD = À0.411; 95% CI, À0.686 to À0.136; T4: SMD = À1.505; 95% CI, À1.852 to À1.158; fT4: SMD = À1.198; 95% CI, À1.472 to À0.925). However, the SMDs for fT3 and TSH were insignificant. Subgroup analysis by age showed significant SMDs for T3, T4, and fT4 in the adult group and a significant decrease in T4 and fT4 in the child group.
Likewise, for patients receiving PHT monotherapy, T4 and fT4 were significantly decreased among epileptic patients (T4: SMD = À1.344; 95% CI, À1.838 to À0.850; fT4: SMD = À0.976; 95% CI, À1.295 to À0.658).
The present study showed a significant effect of VPA on serum T4 and TSH. T4 was significantly decreased whereas TSH levels were increased. (T4: SMD = À0.384; 95% CI, À0.589 to À0.179; TSH: SMD = 0.942; 95% CI, 0.664-1.220).
Discussion
While studies evaluating thyroid function status in epileptic patients suggest that thyroid hormone levels are not directly related to epilepsy, some changes in thyroid function tests could be associated with the prescribed AEDs [50] . Our meta-analysis synthesized all available compatible data reporting the associations between AEDs and thyroid hormones. Our results showed significant and robust alterations in thyroid profiles among patients receiving AEDs, including decrease of T4 and fT4 and increase of TSH. However, T3 and fT3 levels seemed unchanged in patients compared to controls. When we stratified participants by age, similar results were obtained in the child group. With respect to specific AEDs, it was seen that monotherapy with CBZ and PHT was significantly associated with a reduction of T4 and fT4 levels; CBZ was also related with lower T3 levels. Furthermore, there was a significant alteration in T4 and TSH levels among epileptic patients on VPA monotherapy. However, considering the observed heterogeneity, these findings should be interpreted with some caution.
The present study reported significantly reduced T4 and fT4 levels along with elevated TSH levels among patients receiving AEDs. Although it was inconclusive as to whether these changes in the thyroid profile affected the reference values, the changes seemed consistent with hypothyroidism [51] . Previous studies have also found that subclinical hypothyroidism might develop in epileptic patients during AED therapy [12, 18, 21, 35] . However, patients using AEDs did not show clinical manifestations or signs of functional hypothyroidism [7] ; among children, these changes did not seem to affect growth or pubertal development [52] . In other words, clinically significant thyroid disorders occur very rarely [50] . Nevertheless, these results may indicate an increased risk of hypothyroidism among patients using AEDs. As we know, thyroid hormones play an important role on physiological process. Once hypothyroidism appears, it will lead to metabolic syndrome with multiple system involved [53] [54] [55] [56] [57] . Therefore, thyroid hormones should be taken seriously for patients treated with long-term AEDs.
As T3 is derived from transformation of T4 in the peripheral tissues [58] , serum T3 and fT3 levels often remain normal even in severe hypothyroidism and are hence of less sensitivity in hypothyroidism diagnosis [51] . This may be why no significant alteration in T3 and fT3 was observed in our meta-analysis.
The mechanism of the underlying positive association between AEDs and thyroid hormones is still unclear. It is known that more than 99% of circulating thyroid hormones (T3 and T4) are bound to plasma proteins, and fT3 and fT4 do not appear to interfere with thyroxin-binding globulin with higher accuracy and sensitivity in clinical practice. By changing their biosynthesis, secretion, transport, metabolism, and/or excretion, AEDs can cause several degrees of impairment in thyroid-hormone homeostasis [2] . According to current literature, it is most likely that AEDs affect hepatic microsomal enzyme systems and accelerate the metabolism of thyroid hormones. Particularly, liver enzyme-inducing antiepileptic drugs (LEI AEDs) such as CBZ and PHT induced the hepatic P450 enzyme system resulting in the reduction of T4 and fT4, as shown in our study. Moreover, human uridine diphosphate glucuronosyltransferase (UGT) could also be responsible for glucuronidation and play a role in metabolism of thyroid hormones, as high levels of UGT have been observed after AED exposure in some studies [15, 59] . Positive feedback mechanism of the hypothalamic-pituitary-thyroid axis is then activated by the decrease in T4 and fT4 levels [60] . Furthermore, another effect of AEDs on thyroid hormones may be due to the interference of competitive binding of thyroid hormones to thyroxin-binding globulin [30, 32, 33, 39] . Peripheral conversion of T4 to active T4 also increased, consequently leading to a decrease of fT4.
As VPA is an established hepatic enzyme inhibitor, it could have some effect on thyroid hormones. However, the mechanisms of VPA-induced thyroid dysfunction were not well established [21] . Therefore, it is possible that the mechanism of enzyme induction was only partially involved. A VPA-mediated decrease in the concentration of serum T4-binding globulin, displacement from protein binding sites, and decreased T4 5 0 -deiodinase activity are VPA, valproate; CBZ, carbamazepine; LTG, lamotrigine; TPM, topiramate; LEV, levetiracetam; fT4, free thyroxine; TSH, thyroid-stimulating hormone; fT3, free triiodothyronine; AEDs, antiepileptic drugs; NA, not available; PHT, phenytoin; T3, triiodothyronine; T4, thyroxine; PB, phenobarbiturate; OXC, oxcarbazepine. * These agents were used as monotherapy except for ''Various AEDs''. ''Various AEDs'' refers to these which are not detailed explained in literature, including monotherapy, multidrug therapy or mixed. all possible explanations [21] . Studies have also shown the g-aminobutyric acid (GABA)-stimulating properties of VPA, and GABA may depress the release of somatostatin, which inhibits TSH secretion [61, 62] . Furthermore, VPA may lead to zinc and selenium deficiencies, which have an important role in thyroid hormones synthesis [62] . In our analysis, CBZ and PHT were indicated to cause a decrease of T4 and fT4 in the absence of TSH response, possibly owing to the disturbed hypothalamic-pituitary-thyroid axis or a newly formed balance in tissue level such that even the decreased hormone levels were satisfactory enough to perform the necessary metabolic activity [2] . Alterations in thyroid hormone levels seem to be reversible after cessation of AEDs treatment [2, 7, 13] . Verrotti et al. [11] showed normalization of serum T4 and fT4 levels in some CBZ-treated children after medication withdrawal 6 months later. Lossius et al. [63] reported significant increases in serum fT4 in patients with epilepsy 4 months after CBZ withdrawal. Attilakos et al. [64] suggested that normal serum TSH levels were restored in children examined at 3 months after VPA withdrawal.
Our study has some limitations. First, all of the included studies were observational and could not control for all possible confounders, which relatively weakened the evidence. Second, our study did not address or assess whether epilepsy itself played a role in the alteration of thyroid hormones albeit rare, or the prescribed AEDs did. Third, the presented heterogeneity was somewhat high despite stratification and subgroup analyses. Finally, many studies reviewed in our meta-analysis were over 15 years old, and the drugs addressed were older drugs; the new-generation AEDs were not included in the analysis. We observed that only few studies relating to AEDs and thyroid hormones were available in recent literature, of which some studies did not meet our inclusion criteria and hence, the evidence of the association between new AEDs and thyroid hormones was rather limited. Although new-generation AEDs are increasingly featuring in modern day prescriptions, traditional AEDs are still widely used in many countries, especially in developing countries. The International League Against Epilepsy has also recommended the traditional medications as first line drugs [65] . Therefore, we believe that our results have considerable applications and significance in clinical practice and may provide more insight into epilepsy treatment with AEDs. Future better designed studies evaluating thyroid function in the context of serum protein concentrations and liver function are warranted to more fully explore the AED effects on thyroid hormones in patients with epilepsy and should focus on more long-term observation of the interaction between newer generation AEDs and thyroid hormone profiles.
Conclusion
Our meta-analysis suggested that use of AEDs such as CBZ, PHT, and VPA was associated with alteration of thyroid hormones (decrease of T4 and fT4 and increase of TSH levels) among patients with epilepsy. Whether these changes are cause for significant clinical concern is yet to be ascertained. Nevertheless, thyroid function should be paid attention on for patients requiring longterm AED treatment, especially for those with hypothyroidism prior to initiation of treatment.
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